Not medical advice. Talk to your provider before using any peptide. Full disclaimer
Orforglipron
Beginner tier: 0.8 mg, daily · FDA label
Also known as: LY3502970, OWL-833, Foundayo
FDA approval came 50 days after Eli Lilly filed the application. That speed tells you something about the demand for a GLP-1 drug you can swallow. Orforglipron (brand name Foundayo) is the first oral non-peptide GLP-1 receptor agonist to reach the market. It isn't actually a peptide; it's a small molecule that survives stomach acid on its own, no enteric coating or fasting window required. In the ATTAIN-1 trial of 3,127 adults, the highest dose cut body weight by 11.2% at 72 weeks (12.4% among those who stayed on it). Head-to-head with oral semaglutide, GI side effects and quit rates ran higher. Self-pay pricing starts at $149 for the first month through LillyDirect.
What Is Orforglipron?
Orforglipron (Foundayo, CAS 2212020-52-3, molecular formula C48H48F2N10O5, MW 883 Da) is a synthetic small molecule GLP-1 receptor agonist, not a peptide. Eli Lilly developed it as LY3502970, a compound also coded OWL833 [6]. It's the first oral GLP-1 drug that requires no fasting window and no absorption enhancer.
The drug binds within the transmembrane core of the GLP-1 receptor at a different site than semaglutide or native GLP-1. This allosteric mechanism triggers the same downstream cascade: insulin secretion, glucagon suppression, delayed gastric emptying, and appetite reduction through hypothalamic signaling. Oral bioavailability is 77% on the FDA label, and there are zero fasting or water restrictions. Take it any time of day with or without food.
In ATTAIN-1 (n=3,127, 72 weeks)[1], the top dose cut body weight by 11.2%, vs 2.1% on placebo. That dose was 36 mg in the trial and is sold as Foundayo 17.2 mg. People who stayed on treatment lost 12.4%. In ACHIEVE-3 [4], orforglipron 36 mg lowered HbA1c more than oral semaglutide 14 mg (1.91 vs 1.47 points at 52 weeks). In ATTAIN-MAINTAIN [5], people switched from injectable tirzepatide or semaglutide kept 75 to 79% of their weight loss at 52 weeks. On placebo they kept 38 to 49%.
The FDA approved Foundayo on April 1, 2026 for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related comorbidity. In ACHIEVE-3, 9 to 10% stopped orforglipron for side effects, vs 4 to 5% on oral semaglutide. Cardiovascular data now exist for type 2 diabetes. ACHIEVE-4 (n=2,749, Lancet 2026)[3] found major cardiovascular events in 4.2% on orforglipron vs 5.0% on insulin glargine over a median 2 years. That met non-inferiority (HR 0.84), which shows heart safety, not a proven heart benefit. The drug launched in April 2026, and this page has not yet summarized community reports.
How Orforglipron Works
Most GLP-1 drugs are peptides that mimic the gut hormone GLP-1 by binding to the same pocket on the receptor's surface. Orforglipron does something different. At 883 daltons, it's a fraction of the size of semaglutide (4,114 Da) and binds inside the receptor's transmembrane domain rather than the extracellular orthosteric pocket. Specifically, it contacts transmembrane helices 1, 2, 3, and 7 along with extracellular loop 2 (ECL2).
This allosteric binding stabilizes the receptor in an active conformation that preferentially activates Gs-protein signaling. The downstream result is identical to what injectable GLP-1 drugs produce: glucose-dependent insulin secretion from pancreatic beta cells, glucagon suppression from alpha cells, slowed gastric emptying, and reduced appetite via hypothalamic and brainstem GLP-1 receptors.
The small-molecule scaffold makes orforglipron resistant to proteolytic degradation in the GI tract. Stomach acid and digestive enzymes break down peptide-based GLP-1 agonists within minutes; orforglipron passes through intact. Oral bioavailability is 77% on the FDA label, without any absorption enhancers or food restrictions. Hepatic CYP3A4 handles primary metabolism. The label puts the half-life at about 29 to 49 hours. A Phase 1a study measured 25 to 68 hours, depending on dose and treatment duration (Pratt et al.)[2]. Either way, once-daily dosing works. Peak plasma concentration arrives 4 to 8 hours after swallowing the tablet.
Orforglipron Benefits
- Orforglipron benefits center on accessible GLP-1 therapy without injections or complicated dosing rules.
- 11.2% average body weight loss at 72 weeks on the highest dose in ATTAIN-1 (3,127 adults)[1]. Those who stayed on treatment lost 12.4%. Overall, 54.6% lost 10% or more.
- No food, water, or fasting rules. Oral semaglutide (Rybelsus) must be taken on an empty stomach with up to 4 oz of water, then 30 minutes before eating.
- Lowered HbA1c more than oral semaglutide 14 mg head-to-head in ACHIEVE-3 (1.91 vs 1.47 points at 52 weeks)[4].
- Triglycerides, non-HDL cholesterol, systolic blood pressure, and waist circumference all improved across ATTAIN-1 dose groups.
- People switched from injectable tirzepatide or semaglutide kept 75 to 79% of their weight loss at 52 weeks (ATTAIN-MAINTAIN)[5]. Placebo kept 38 to 49%.
Orforglipron: Science vs Community Consensus
FDA-approved oral non-peptide GLP-1 agonist.
Read the evidence (key study, limitations)
Phase 3 shows 11.2–12.4% body weight loss (ITT/efficacy estimand) at highest dose over 72 weeks. Superior to oral semaglutide 14mg for HbA1c reduction in head-to-head ACHIEVE-3. Side-effect discontinuation (6–10% by dose vs 3% placebo on the label) ran higher than oral semaglutide in ACHIEVE-3.
ATTAIN-1 (Phase 3, n=3,127, 72 weeks, NEJM 2025, PMID 40960239); ACHIEVE-3 (Phase 3 head-to-head vs. oral semaglutide, n=1,698, Lancet 2026, PMID 41765029)
Phase 3 weight-loss data run 72 weeks; cardiovascular outcomes data come only from ACHIEVE-4 in type 2 diabetes (MACE-4 HR 0.84, 95% CI 0.59 to 1.20 vs insulin glargine, non-inferior, superiority not shown); higher GI AE and discontinuation rates than oral semaglutide in ACHIEVE-3; T2D indication not yet FDA-approved in US; no post-market real-world data summarized here yet (launched April 2026)
Not yet summarized.
Read the reports (what users report 3, common issues 3)
The drug launched in April 2026, and this page has not reviewed community reports since then.
- No injections
- No food/water restrictions (unlike oral semaglutide)
- No needle anxiety barrier
- GI side effects during titration steps
- Higher nausea rate vs. injectables
- Cash pay cost if uninsured
The drug launched in April 2026. This page has not yet reviewed community reports, so alignment stays science-only until it does.
Orforglipron Dosage Guide
| Level | Dose | Frequency |
|---|---|---|
| Beginner | 0.8 mg | Daily |
| Moderate | 5.5 mg | Daily |
| Aggressive | 17.2 mg | Daily |
Oral tablet. No vials, no syringes, no reconstitution math. That alone makes orforglipron the simplest GLP-1 drug to start.
Titration schedule matters more than most beginners realize. You start at 0.8 mg daily for a full 30 days before moving to 2.5 mg. Then 5.5 mg for another 30 days. After that, you can escalate to 9 mg, 14.5 mg, or 17.2 mg based on how your body responds. Skipping steps or rushing the schedule significantly increases nausea and GI side effects.
The detail that catches people off guard: if you miss 7 or more consecutive doses, you restart the entire titration from 0.8 mg. Not from where you left off.
Swallow the tablet whole. Don't crush, break, or chew it. Take it any time of day, food or no food, water or no water. No awkward 30-minute fasting window like Rybelsus.
Constipation hits harder than most expect (20 to 27% across doses in the label's weight trials, vs 9% on placebo). Start extra fiber and fluids on day 1, not after symptoms appear. Each dose escalation step tends to bring a fresh wave of nausea for 5 to 7 days; plan increases during low-stress weeks.
Cycling
No scheduled off period.
Intended for continuous long-term use. Weight regain expected after stopping: same as other GLP-1 drugs. If you miss 7 or more consecutive days, restart the titration schedule.
Continuous indefinite use is per FDA label design: weight regain is rapid and substantial on discontinuation (same as injectable GLP-1 drugs). No receptor desensitization, antibody formation, or hormonal axis suppression concerns apply to this small molecule. Cycling is not medically recommended.
- Weight regain typically begins within 4–8 weeks of stopping (expected, not a treatment failure)
- Return of pre-treatment appetite patterns and hunger drive
- HbA1c creep in T2D patients after discontinuation
Or use the universal Peptide Calculator for any peptide.
Orforglipron Protocols by Goal
Expected: 11.2% (ITT) to 12.4% (efficacy estimand) mean body weight loss at 72 weeks on the top dose in ATTAIN-1 (PMID 40960239). The FDA label reports 11.1% for 17.2 mg. 54.6% of patients lost ≥10% at that dose
Monitor: Monitor renal function during GI-heavy titration steps (AKI risk from dehydration). Check heart rate periodically (orforglipron increases HR more than oral semaglutide). Oral contraceptive users: switch to non-oral method or use barrier contraception for 30 days after initiation and each dose escalation.
How to Use Orforglipron
- 1Pick a consistent time of day that works for your schedule
Morning, evening, or midday all work fine.
- 2Take one tablet by mouth
Swallow it whole with whatever amount of water you prefer. No crushing, breaking, or chewing.
- 3Food doesn't matter
You can take it on an empty stomach, with a meal, or with a snack. No restrictions.
- 4Step 4
Follow the titration schedule exactly: 0.8 mg daily for 30 days, then 2.5 mg for 30 days, then 5.5 mg for 30 days, then your provider will move you to 9 mg, 14.5 mg, or 17.2 mg.
- 5If you miss a dose, take it as soon as you remember
Don't double up.
- 6Step 6
If you miss 7 or more consecutive days, restart from 0.8 mg and work through the full titration again.
- 7Step 7
Store tablets at room temperature, 20 to 25 degrees Celsius (68 to 77 degrees Fahrenheit). Excursions to 15 to 30 degrees Celsius are fine.
- 8No syringes, needles, or refrigeration involved
This is a standard oral medication.
Alternative Routes
No alternative routes studied or available
Unlike oral semaglutide, no fasting or water volume restrictions. Swallow tablet whole only.
Orforglipron Stacking Protocols
Works With
Used as background therapy in ACHIEVE-3 T2D population; complementary glycemic mechanism (insulin sensitizer + GLP-1 agonist). No interaction concerns.
Continue existing metformin dose; no adjustment required unless hypoglycemia occurs
Avoid
Concurrent use of two GLP-1 receptor agonists is not recommended per FDA label; no combination data
Do not combineDual GIP/GLP-1 agonist: concurrent GLP-1 agonism not recommended per FDA label; no safety data for combination
Do not combineGLP-1 receptor agonist: concurrent use with another GLP-1 agonist is not recommended per FDA label
Do not combineTriple GIP/GLP-1/glucagon agonist: includes GLP-1 agonism; concurrent use is not recommended
Do not combineSubstantially reduce orforglipron plasma levels, potentially eliminating efficacy. Avoid concurrent use.
Do not combineEstimated Cost
Pricing updated 2026-04-09
Orforglipron Side Effects
The black box warning comes first. It's the GLP-1 class warning for thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), which other GLP-1 drugs caused in rats and mice. Orforglipron isn't active at the rodent GLP-1 receptor and caused no tumors in rodent studies, so its human risk is unknown (FDA label). Anyone with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) should not take this drug.
Pancreatitis is the second concern. In the two weight trials behind the label, 6 people on orforglipron had confirmed acute pancreatitis, vs 1 on placebo. Severe, persistent abdominal pain radiating to the back warrants immediate medical evaluation and discontinuation.
GI side effects are the daily reality for most users during dose escalation. In those trials, nausea hit 26 to 35% across doses (10% on placebo). Constipation ran 20 to 27%, diarrhea 21 to 25%, vomiting 13 to 24%, and dyspepsia 12 to 16%. Abdominal pain, burping, heartburn, and gas round out the GI profile. GI side effects made 3 to 6% stop treatment, vs 0.7% on placebo. In the ACHIEVE-3 comparison, 9 to 10% stopped orforglipron for any side effect, vs 4 to 5% on oral semaglutide [4].
Headache, fatigue, and hair loss appear in the trial data. Heart rate rose 4 to 5 bpm on average in the label's trials (0.5 bpm on placebo). In ACHIEVE-3, pulse rose more on orforglipron than on oral semaglutide (3.7 to 4.7 vs 1.0 to 1.5 bpm). Resting heart rate should be checked at baseline and at each dose escalation.
Acute kidney injury is possible during severe GI episodes. Dehydration from vomiting or diarrhea can drop renal perfusion quickly. Renal function monitoring during GI-heavy titration steps is recommended.
Gallbladder disease (cholelithiasis, cholecystitis) carries the same class-level association seen with other GLP-1 drugs.
Oral hormonal contraceptives may lose effectiveness during initiation and each dose escalation. Gastric emptying delay alters absorption timing. The label recommends switching to a non-oral contraceptive method or adding barrier contraception for 30 days after starting and after each dose increase.
Stop orforglipron and contact a provider if you notice a neck mass, persistent hoarseness, difficulty swallowing, severe abdominal pain that doesn't resolve, or signs of a serious allergic reaction. Pregnancy isn't a listed contraindication, but the label says to stop Foundayo once pregnancy is recognized, since weight loss offers no benefit in pregnancy. Women of reproductive potential should use reliable contraception during treatment.
Common Issues & Solutions
Nausea peaks at each dose escalation step: plan dose increases for low-stress weeks; eat smaller, bland meals during the first 5–7 days of each new dose
If GI side effects are severe at a given step, hold at the current dose for 2–4 extra weeks before escalating rather than stopping the drug
Missed ≥7 consecutive doses: restart titration from 0.8 mg: skipping the restart significantly increases GI AE risk at the higher dose
Oral contraceptive users: switch to non-oral formulation before starting; if staying oral, add barrier contraception for 30 days after each escalation step
Constipation (20 to 27% in the label's trials) is as significant as nausea. Increase fluid intake and dietary fiber proactively from day 1, not after onset
Ask AI about this page
Ask AI for a second opinion on Orforglipron dosing and side effects
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- Known serious hypersensitivity to orforglipron or any excipient
- Other GLP-1 receptor agonists: use together is not recommended on the label (a limitation of use, not a contraindication)
- Pregnancy: not a label contraindication; the label says to stop Foundayo once pregnancy is recognized
Drug Interactions
- Strong CYP3A4 inhibitors (e.g., clarithromycin, which raised orforglipron exposure 3.5-fold): the label caps Foundayo at 9 mg daily. It says to avoid those that also inhibit OATP1B, such as ritonavir
- Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin): avoid per the label; carbamazepine cut orforglipron exposure 82%. With moderate inducers, the label says to monitor response
- Insulin and sulfonylureas: increased hypoglycemia risk; dose reduction of the secretagogue often needed
- Oral medications with narrow therapeutic windows: gastric emptying delay may alter absorption timing; monitor drugs like warfarin, digoxin, and levothyroxine
- Concurrent use of two GLP-1 receptor agonists is not recommended per FDA label; no combination data
- Dual GIP/GLP-1 agonist: concurrent GLP-1 agonism not recommended per FDA label; no safety data for combination
- GLP-1 receptor agonist: concurrent use with another GLP-1 agonist is not recommended per FDA label
- Triple GIP/GLP-1/glucagon agonist: includes GLP-1 agonism; concurrent use is not recommended
Product Quality
Orforglipron is a synthetic small molecule: it cannot be replicated by compounding pharmacies and is not on the FDA drug shortage list. No gray market supply exists. All supply flows through licensed US pharmacies, LillyDirect, or telehealth platforms. Counterfeit risk is essentially zero in the current early-access market.
- Only obtain through licensed US pharmacies, LillyDirect, or verified telehealth platforms
- Confirm the tablet is authentic Foundayo: any product claimed to be "compounded orforglipron" is fraudulent
- No compounded versions exist or are legal; small molecule structure is not reproducible by peptide compounders
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| Renal function (eGFR, serum creatinine) | Baseline; repeat during GI-heavy escalation phases if nausea/vomiting/diarrhea is significant | eGFR >60 mL/min/1.73m² preferred; no dose adjustment per label for renal impairment, but monitor closely |
| Heart rate (resting) | Baseline; each dose escalation visit | Clinically significant if >10 bpm sustained elevation above baseline; evaluate if symptomatic tachycardia |
| HbA1c | Baseline; every 3 months in T2D patients | <7.0% (T2D standard); <5.7% (normoglycemia threshold) |
| Body weight | Monthly | About 11–12% by week 72 at maximum dose (ATTAIN-1) |
| Liver enzymes (ALT, AST) | Baseline; periodically if symptomatic | Not listed |
| Fasting lipid panel (triglycerides, non-HDL, total cholesterol) | Baseline; 12–24 weeks after reaching maintenance dose | Not listed |
| Systolic blood pressure | Baseline; every 3 months | Not listed |
Acute kidney injury risk from volume depletion secondary to GI adverse events
Orforglipron increases resting HR more than oral semaglutide (ACHIEVE-3 data)
Glycemic response; dose titration decisions; hypoglycemia risk with co-medications (insulin/sulfonylureas)
Primary efficacy metric; informs dose escalation vs. maintenance decision
Orforglipron is primarily cleared via hepatic CYP3A4 metabolism
ATTAIN-1 showed significant triglyceride and non-HDL cholesterol reductions; confirms metabolic benefit
ATTAIN-1 showed meaningful SBP reductions; also monitors for dehydration during GI-active periods
Orforglipron Before and After
Starting dose 0.8mg. Mild appetite suppression begins. GI side effects (nausea, stomach discomfort) most likely during this period. Minimal weight change expected.
Titrating through 2.5mg and 5.5mg. Appetite reduction becomes more noticeable. Early weight loss of 2-4% body weight. Nausea typically fades as each dose level stabilizes.
Reaching maintenance doses (9-17.2mg). Steady weight loss averaging 0.5-1 lb/week. Measurable improvements in waist circumference and metabolic labs.
Weight loss approaches 10-12% average at the highest dose based on ATTAIN-1 data. Triglycerides, non-HDL cholesterol, and blood pressure improve. Rate of loss slows as new equilibrium is reached.
What to Expect
Weeks 1 through 4 (0.8 mg): The starting dose is sub-therapeutic by design. Don't expect meaningful weight change yet. GI side effects, especially nausea and stomach discomfort, are most likely during week 1. Occasional vomiting can happen. The purpose of this phase is purely GI adaptation. This page hasn't summarized community reports yet; the drug launched in April 2026.
Weeks 5 through 12 (2.5 to 5.5 mg): Appetite suppression becomes noticeable as the dose climbs, and early weight loss starts to show. Nausea tends to fade 5 to 7 days after each dose step; constipation and diarrhea are reported at these levels.
Weeks 13 through 20 (9 to 14.5 mg): This is the entry into maintenance territory. Weight loss steadies at roughly 0.5 to 1 lb per week. Waist circumference, triglycerides, non-HDL cholesterol, and systolic blood pressure begin to show measurable improvements. GI events are generally tolerable for patients who titrated slowly. Some trial participants reported hair loss starting around this point.
Weeks 21 through 72 (17.2 mg): Weight loss approaches the 11.2% average seen in ATTAIN-1 (ITT analysis), or 12.4% among those who stayed on treatment. The rate of loss slows as the body reaches a new equilibrium. Metabolic lab values continue to improve. Heart rate elevation is more prominent at this dose than with oral semaglutide per ACHIEVE-3 data. Constipation and alopecia were reported in trial subsets at this stage.
Detailed Timeline: Science vs Community
Sub-therapeutic dose: minimal weight change expected. GI side effects (nausea, stomach discomfort) are most common during initiation week.
Not yet reviewed: the drug launched in April 2026.
Appetite suppression becomes noticeable, and early weight loss starts. GI effects generally improve as each dose level stabilizes.
Not yet reviewed.
Steady weight loss averaging 0.5–1 lb/week. Measurable improvements in waist circumference, triglycerides, non-HDL cholesterol, systolic BP.
Not yet reviewed.
Weight loss plateau approaching 11.2% mean reduction (ITT) or 12.4% (among those who stayed on treatment). Rate of loss slows as new set point is reached. Metabolic labs continue improving.
Not yet reviewed.
Pharmacokinetics
Source: FDA label (Foundayo, section 12.3): t½ about 29-49h; Pratt et al. Phase 1a (PMID 37344954): 48-68h at day 28 across the dose range
Pharmacokinetics: Active Dose Over Time
t½ = ~29-49 hoursDisclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Is Orforglipron Legal?
Orforglipron (Foundayo) received FDA approval on April 1, 2026 for chronic weight management in adults with a BMI of 30 or greater, or BMI of 27 or greater with at least one weight-related comorbidity. It was the fifth drug approved under the FDA's National Priority Voucher program. Orforglipron is not approved for blood sugar control in type 2 diabetes in the United States, though the Phase 3 ACHIEVE trials tested that use. In the UK, the MHRA authorized Foundayo on August 10, 2026 for weight management and for glycemic control in type 2 diabetes (MHRA press release on GOV.UK). It was the first authorization of orforglipron in Europe.
Orforglipron is a patented small molecule manufactured exclusively by Eli Lilly. No generic versions exist. It is not on the FDA drug shortage list, so compounded copies of Foundayo are not permitted. Any product sold as "compounded orforglipron" is fraudulent. Obtain it only through licensed US pharmacies, LillyDirect, or verified telehealth platforms.
WADA status has not been determined for orforglipron specifically, though GLP-1 receptor agonists are not currently prohibited in competition.
This content is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare provider before starting any medication.
Who Should Consider Orforglipron
- Adults with BMI ≥30 (obesity)
- Adults with BMI ≥27 plus at least one weight-related comorbidity (hypertension, dyslipidemia, T2D, OSA)
- People who prefer oral medication over injections
- Patients switching from injectable GLP-1s who want to maintain weight loss orally
- Adults with type 2 diabetes and overweight or obesity seeking weight loss (studied in ATTAIN-2)
Related Peptides
What Changed for Orforglipron
- Safety
Corrected Oct 13, 2026: orforglipron caused no rodent thyroid tumors; its boxed warning is the GLP-1 class warning, per the Foundayo label.
Before: Thyroid C-cell tumors developed in rodent studies at clinically relevant exposures; constipation 30%; GI discontinuation 3.5 to 10%; pregnancy called a contraindication After: Orforglipron is not active in rats or mice and caused no rodent tumors (class warning); constipation 20 to 27%; 3 to 6% stopped for GI side effects vs 0.7%; stop once pregnancy is recognized
What this does not mean: The boxed warning and the MTC and MEN 2 contraindication stay, and human risk is unknown. The page also now gives label rates for constipation and for stopping over GI side effects.
Source: Foundayo (orforglipron) prescribing information (openFDA label record, SPL version 10, effective Jul 29, 2026) (opens in a new tab) · Saved copy
- Safety
Corrected Oct 13, 2026: orforglipron is capped at 9 mg daily with strong CYP3A4 inhibitors, and strong inducers are to be avoided, per the Foundayo label.
Before: CYP3A4 inhibitors: monitor closely; CYP3A4 inducers: may reduce efficacy; GLP-1 combinations called contraindicated per FDA label After: Strong CYP3A4 inhibitors: 9 mg daily cap, avoid those that also inhibit OATP1B; strong inducers: avoid (carbamazepine cut exposure 82%); GLP-1 combinations: not recommended per label
What this does not mean: The dose tiers on this page are unchanged. Other GLP-1 drugs alongside it are not recommended on the label; the page had called the combination contraindicated.
Source: Foundayo (orforglipron) prescribing information (openFDA label record, SPL version 10, effective Jul 29, 2026) (opens in a new tab) · Saved copy
- Safety
Corrected Oct 13, 2026: other GLP-1 drugs and pregnancy are label cautions for orforglipron, not contraindications, per the Foundayo label.
Before: Concurrent use with other GLP-1 receptor agonists; pregnancy or planning to become pregnant (both listed as contraindications) After: Other GLP-1 receptor agonists: not recommended together (a limitation of use); pregnancy: stop once recognized (a label caution)
What this does not mean: Do not combine it with another GLP-1 drug, and stop it once pregnancy is recognized. The label contraindicates MTC or MEN 2 history and serious hypersensitivity.
Source: Foundayo (orforglipron) prescribing information (openFDA label record, SPL version 10, effective Jul 29, 2026) (opens in a new tab) · Saved copy
- Evidence
Corrected Oct 13, 2026: in ACHIEVE-3, 9 to 10% stopped orforglipron for side effects vs 4 to 5% on oral semaglutide, about double, per PubMed.
Before: GI discontinuation about 4x higher than oral semaglutide in the ACHIEVE-3 comparison After: In ACHIEVE-3, 9 to 10% stopped orforglipron for side effects vs 4 to 5% on oral semaglutide (PMID 41765029)
What this does not mean: The page had said about 4 times. Orforglipron still lowered HbA1c more than oral semaglutide in the same trial, and its pulse rise was larger (3.7 to 4.7 vs 1.0 to 1.5 bpm).
Source: Lancet 2026, Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
- Dosing
Corrected Oct 6, 2026: the dosing source and FAQ now give 2026, not 2025, as the year of Foundayo's first US approval, per the FDA record.
Source: Drugs@FDA record for Foundayo (orforglipron), NDA 220934 (openFDA) (opens in a new tab) · Saved copy
- Evidence
ACHIEVE-4 found MACE-4 in 4.2% on orforglipron vs 5.0% on insulin glargine (HR 0.84), meeting non-inferiority, published Sep 30, 2026, per The Lancet.
What this does not mean: Non-inferiority, not a shown heart benefit (95% CI 0.59 to 1.20). It enrolled adults with type 2 diabetes, an indication Foundayo does not have in the US.
Source: Lancet 2026, Cardiovascular safety of orforglipron versus insulin glargine (ACHIEVE-4) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
- Safety
In ACHIEVE-J, 14% stopped orforglipron 36 mg for side effects vs 5% on 3 mg over 52 weeks, published Aug 17, 2026, per Lancet Diabetes Endocrinol.
What this does not mean: An open-label safety trial in 401 Japanese adults with type 2 diabetes, with no placebo arm. Most side effects were mild, and none had severe hypoglycemia.
Source: Lancet Diabetes Endocrinol 2026, Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J) (opens in a new tab) · Archived snapshot (opens in a new tab)
- Regulatory
FDA granted original approval to Foundayo (orforglipron, NDA 220934) on Apr 1, 2026, per Drugs@FDA.
What this does not mean: The approval covers the Foundayo product and its labeled uses only.
Source: Drugs@FDA record for Foundayo, NDA 220934 (openFDA) (opens in a new tab) · Saved copy
Peptide Schedule Research TeamReviewed Oct 13, 202611 Citations
References
- [1]ATTAIN-1: ATTAIN-1: Orforglipron for Obesity (Phase 3) (opens in a new tab)(n=3,127)PubMed (opens in a new tab)PubMed
- [2]Phase 1a: Orforglipron Single- and Multiple-Ascending-Dose Study (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]ACHIEVE-4: ACHIEVE-4: Cardiovascular Safety of Orforglipron vs Insulin Glargine in Type 2 Diabetes (Phase 3, Lancet 2026) (opens in a new tab)(n=2,749)PubMed (opens in a new tab)PubMed
- [4]ACHIEVE-3: ACHIEVE-3: Orforglipron vs Oral Semaglutide in Type 2 Diabetes (Phase 3, Lancet 2026) (opens in a new tab)(n=1,698)PubMed (opens in a new tab)PubMed
- [5]ATTAIN-MAINTAIN: ATTAIN-MAINTAIN: Orforglipron for Maintenance of Body Weight Reduction (Phase 3b, Nat Med 2026) (opens in a new tab)(n=376)PubMed (opens in a new tab)PubMed
- [6]Structural basis for GLP-1 receptor activation by LY3502970 (OWL833), an orally active nonpeptide agonist (Kawai et al., PNAS 2020) (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
- ATTAIN-2: Orforglipron for Obesity with Type 2 Diabetes (Phase 3, Lancet) (opens in a new tab)PubMed 41275875PubMed
- Phase 2: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity (NEJM) (opens in a new tab)PubMed 37351564PubMed
- Orforglipron Comprehensive Review (IJMS 2025) (opens in a new tab)PubMed 41683830Review
- FDA Approval: Foundayo Prescribing Information (opens in a new tab)FDA Label
- UK first in Europe to authorise orforglipron for weight management and type 2 diabetes (MHRA press release, GOV.UK, 10 Aug 2026) (opens in a new tab)Review
Related Resources
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is Orforglipron?
Popular. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
79 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
High search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.